California-based Intersect ENT files for an initial public offering worth up to $80 million in support of its drug-eluting implants for chronic sinusitis.
Drug-eluting devices maker Intersect ENT hopes to raise as much as $80 million in a newly registered initial public offering, according to SEC documents filed this week.
Hey, check out all the research scientist jobs. Post your resume today!
